Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

CLDX | Celldex Therapeutics Inc.

Index	RUT	P/E	-	EPS (ttm)	-2.40	Insider Own	1.38%	Shs Outstand	47.20M	Perf Week	4.11%
Market Cap	1.29B	Forward P/E	-	EPS next Y	-2.98	Insider Trans	0.00%	Shs Float	46.61M	Perf Month	-3.39%
Income	-113.13M	PEG	-	EPS next Q	-0.68	Inst Own	107.28%	Short Float / Ratio	13.06% / 14.25	Perf Quarter	-22.00%
Sales	3.25M	P/S	397.57	EPS this Y	-9.76%	Inst Trans	2.46%	Short Interest	6.09M	Perf Half Y	-21.39%
Book/sh	5.87	P/B	4.65	EPS next Y	-13.31%	ROA	-32.22%	Target Price	59.57	Perf Year	-1.19%
Cash/sh	5.32	P/C	5.14	EPS next 5Y	-	ROE	-35.21%	52W Range	24.89 - 48.40	Perf YTD	-38.66%
Dividend	-	P/FCF	-	EPS past 5Y	26.01%	ROI	-40.51%	52W High	-43.51%	Beta	2.14
Dividend %	-	Quick Ratio	16.93	Sales past 5Y	-13.34%	Gross Margin	13.18%	52W Low	9.84%	ATR	1.09
Employees	148	Current Ratio	16.93	Sales Q/Q	64.42%	Oper. Margin	-3725.25%	RSI (14)	44.86	Volatility	3.87% 3.77%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	16.17%	Profit Margin	-3475.70%	Rel Volume	1.36	Prev Close	26.51
Shortable	Yes	LT Debt/Eq	0.01	Earnings	Aug 08 AMC	Payout	-	Avg Volume	427.23K	Price	27.34
Recom	1.57	SMA20	-0.31%	SMA50	-10.65%	SMA200	-25.43%	Volume	583,043	Change	3.13%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-22-23	Initiated	Wells Fargo	Underweight	$21
Sep-17-21	Initiated	Jefferies	Buy	$66
Sep-10-21	Initiated	SVB Leerink	Outperform	$68
Jul-22-21	Initiated	Guggenheim	Buy	$66
Feb-21-20	Initiated	Cantor Fitzgerald	Overweight	$8
Aug-01-17	Resumed	H.C. Wainwright	Buy	$10
Nov-07-16	Initiated	Aegis Capital	Buy
Mar-08-16	Downgrade	Jefferies	Buy → Hold
Mar-07-16	Downgrade	Wedbush	Outperform → Neutral	$4
Mar-07-16	Downgrade	Leerink Partners	Outperform → Mkt Perform
Mar-07-16	Downgrade	Guggenheim	Buy → Neutral
Mar-01-16	Initiated	H.C. Wainwright	Buy	$25
Aug-11-15	Reiterated	ROTH Capital	Buy	$43 → $39
Aug-11-15	Reiterated	Oppenheimer	Outperform	$45 → $42
Aug-11-15	Reiterated	Brean Capital	Buy	$35 → $31
Jun-02-15	Reiterated	WBB Securities	Strong Buy	$30 → $40
Nov-17-14	Reiterated	ROTH Capital	Buy	$40 → $43
Mar-04-14	Reiterated	Oppenheimer	Outperform	$40 → $36
Jul-08-13	Reiterated	Cantor Fitzgerald	Buy	$16 → $24
Mar-08-13	Reiterated	Cantor Fitzgerald	Buy	$13 → $16

Show Previous Ratings

Sep-26-23 07:01AM	Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023 (GlobeNewswire)
Sep-25-23 08:31AM	Celldex Therapeutics to Present at Cantor Global Healthcare Conference (GlobeNewswire)
Aug-22-23 09:35AM	AppLovin upgraded, Genpact downgraded: Wall Street's top analyst calls (The Fly) -5.20%
Aug-08-23 05:30PM	Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:21PM	Celldex: Q2 Earnings Snapshot (AP Finance)
04:01PM	Loading…
04:01PM	Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-11-23 08:01AM	Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (GlobeNewswire)
Jul-06-23 08:01AM	Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (GlobeNewswire)
Jun-10-23 10:45AM	Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023 (GlobeNewswire)
Jun-08-23 04:01PM	Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023 (GlobeNewswire)
Jun-02-23 08:01AM	Celldex Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-31-23 08:01AM	Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies (GlobeNewswire)
May-23-23 06:10AM	Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
May-15-23 08:01AM	Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023 (GlobeNewswire)
May-04-23 06:05PM	Celldex Therapeutics (CLDX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:03PM	Loading…
05:03PM	Celldex: Q1 Earnings Snapshot (AP Finance)
04:01PM	Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-18-23 05:58AM	Strength Seen in Celldex (CLDX): Can Its 7.1% Jump Turn into More Strength? (Zacks) +5.92%
Apr-12-23 08:13AM	Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 42%? (Simply Wall St.)
Mar-29-23 09:01AM	Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire)
Mar-02-23 05:40AM	Celldex Therapeutics Full Year 2022 Earnings: Revenues Beat Expectations, EPS In Line (Simply Wall St.)
Feb-28-23 04:01PM	Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-27-23 10:25AM	Why Celldex Therapeutics Shares Are Trading Higher Today (Benzinga) +7.30%
Feb-26-23 09:00AM	Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023 (GlobeNewswire)
Feb-16-23 04:01PM	Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors (GlobeNewswire)
Feb-15-23 07:00AM	Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-03-23 07:01AM	Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023 (GlobeNewswire)
Jan-18-23 02:38PM	As Celldex Recovers, Here's My Strategy (TheStreet.com)
Dec-06-22 06:00AM	Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022 (GlobeNewswire)
Dec-02-22 09:31AM	Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022 (GlobeNewswire)
09:45AM	Loading…
Nov-27-22 09:45AM	We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely (Simply Wall St.)
Nov-10-22 04:01PM	Celldex to Participate in Upcoming November Investor Conferences (GlobeNewswire) +15.99%
Nov-09-22 05:25PM	Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -5.67%
04:01PM	Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-22 10:01AM	Spero Therapeutics, Inc. (SPRO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Nov-01-22 10:01AM	Earnings Preview: Celldex Therapeutics (CLDX) Q3 Earnings Expected to Decline (Zacks)
Aug-08-22 05:25PM	Celldex Therapeutics (CLDX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-21-22 08:00AM	Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria (GlobeNewswire)
Jul-08-22 09:26AM	Billionaire Andreas Halvorsen Bets Big on These 2 High-Upside Stocks (TipRanks)
Jul-06-22 09:55AM	Wall Street Analysts See a 169% Upside in Celldex (CLDX): Can the Stock Really Move This High? (Zacks)
07:20AM	Celldex (CLDX) Surges 9%: Is This an Indication of Further Gains? (Zacks)
Jul-05-22 03:57PM	Read How Cantor Views Celldex Therapeutics' Barzolvolimab Data (Benzinga) +9.03%
Jul-04-22 11:49AM	Celldex (CLDX) Down on Interim Data From Phase Ib Study in CSU (Zacks)
Jul-01-22 04:11PM	Celldex Therapeutics Skids As It Takes On A Blockbuster Roche, Novartis Drug (Investor's Business Daily) -15.80%
10:11AM	Celldex's Barzolvolimab Shows Rapid, Durable Responses In Early Urticaria Study (Benzinga)
Jun-30-22 06:01PM	Celldex Therapeutics Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022 (GlobeNewswire)
Jun-22-22 09:24AM	Celldex (CLDX) Initiates Phase II Chronic Skin Disorder Study (Zacks)
Jun-21-22 08:00AM	Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (GlobeNewswire)
Jun-20-22 10:35AM	We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely (Simply Wall St.)
Jun-16-22 04:01PM	Celldex Announces Two New Appointments to its Board of Directors (GlobeNewswire)
Jun-06-22 04:05PM	Celldex to Present at the 2022 Jefferies Global Healthcare Conference (GlobeNewswire)
May-19-22 09:23AM	Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022 (GlobeNewswire)
May-11-22 08:13AM	7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years (InvestorPlace)
May-06-22 08:10AM	Celldex Therapeutics' (NASDAQ:CLDX) investors will be pleased with their enviable 762% return over the last three years (Simply Wall St.)
May-05-22 05:55PM	Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -5.57%
04:01PM	Celldex Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-04-22 08:25AM	Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Feb-28-22 04:01PM	Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-22-22 04:01PM	Celldex to Host Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Conference Call (GlobeNewswire)
Feb-17-22 03:07AM	Top 10 Biotech Stocks to Buy According to Jeremy Greens Redmile Group (Insider Monkey) -5.17%
Feb-13-22 07:47AM	Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 29%? (Simply Wall St.)
Feb-10-22 04:05PM	Celldex to Present at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Feb-02-22 01:38PM	HC Advisors, LLC Buys Vanguard Short-Term Government Bond ETF, Apellis Pharmaceuticals Inc, ... (GuruFocus.com)
Jan-10-22 08:40AM	Is the Options Market Predicting a Spike in Celldex (CLDX) Stock? (Zacks)
Dec-15-21 04:57AM	We're Interested To See How Celldex Therapeutics (NASDAQ:CLDX) Uses Its Cash Hoard To Grow (Simply Wall St.)
01:38AM	VIP Growth Opportunities Portfolio Buys Uber Technologies Inc, Lightspeed Commerce Inc, Chewy ... (GuruFocus.com)
Dec-11-21 06:53PM	Hedge Funds Are Crazy About Celldex Therapeutics, Inc. (CLDX) (Insider Monkey)
Dec-08-21 08:01AM	Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis (GlobeNewswire)
Nov-12-21 07:00AM	Celldex Presents Positive Preclinical Data from PD-1/ILT4 Bispecific Antibody Program CDX-585 at SITC 2021 (GlobeNewswire) -5.47%
Nov-11-21 07:01AM	Celldex to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-09-21 06:15PM	Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Celldex Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-28-21 03:05PM	Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-25-21 11:51AM	Should I Avoid Celldex Therapeutics, Inc. (CLDX)? (Insider Monkey)
Sep-29-21 08:13AM	The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug (Benzinga)
12:00AM	Celldex Presents Positive Data on Symptom Control and Quality of Life Measurements that Further Support CDX-0159 Clinical Benefit in Phase 1b Study in Chronic Inducible Urticaria at EADV 2021 (GlobeNewswire)
Sep-24-21 07:01AM	Celldex to Present at the 2021 Cantor Virtual Global Healthcare Conference (GlobeNewswire)
Sep-23-21 08:01AM	Celldex Announces Upcoming Presentation of CDX-0159 Phase 1b Results in Inducible Urticaria at the 2021 European Academy of Dermatology and Venereology (EADV) 30th Congress (GlobeNewswire)
Sep-16-21 07:01AM	Investors in Celldex Therapeutics (NASDAQ:CLDX) have made a enviable return of 729% over the past three years (Simply Wall St.)
Sep-14-21 10:31AM	Celldex (CLDX) Initiates Subcutaneous Skin Disorder Drug Study (Zacks)
Sep-13-21 09:01AM	Celldex Announces Initiation of CDX-0159 Subcutaneous Formulation Study (GlobeNewswire)
Aug-25-21 03:55PM	3 Strong Buy Stocks Showing Monster Growth (TipRanks)
Aug-05-21 06:05PM	Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +6.38%
04:01PM	Celldex Reports Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-29-21 03:05PM	Will Celldex Therapeutics (CLDX) Report Negative Q2 Earnings? What You Should Know (Zacks)
Jul-24-21 07:04AM	How Good Were Celldex Therapeutics' Latest Clinical Results? (Motley Fool)
Jul-18-21 03:39AM	What Is The Ownership Structure Like For Celldex Therapeutics, Inc. (NASDAQ:CLDX)? (Simply Wall St.)
Jul-16-21 04:01PM	Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) -7.34%
Jul-14-21 03:21PM	Biotech Stock Roundup: BIIB & PRTA Provide Updates, CLDX Up on Positive Data & More (Zacks)
08:39AM	Celldex (CLDX) Up Almost 40% Since Skin Disorder Study Data (Zacks)
06:41AM	Celldex Therapeutics Raises $250M Via Equity To Support Development Of Skin Disease Candidate (Benzinga)
Jul-13-21 08:30PM	Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock (GlobeNewswire) +9.66%
03:19PM	Why Celldex Therapeutics Stock Is Jumping Again Today (Motley Fool)
Jul-12-21 04:27PM	Celldex Therapeutics Stock Rocketed Above A Profit-Taking Zone Here's Why (Investor's Business Daily) +25.49%
04:01PM	Celldex Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
03:54PM	You Should Know About Monday's 2 Big Nasdaq Winners (Motley Fool)
03:32PM	Where Do Hedge Funds Stand On Celldex Therapeutics, Inc. (CLDX)? (Insider Monkey)
11:09AM	Why Celldex Therapeutics Stock Is Skyrocketing Today (Motley Fool)
08:38AM	5 Top Stock Gainers for Monday: Celldex, Sgoco, State Auto (TheStreet.com)

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KELER TIBOR	EXECUTIVE VP & CSO	Dec 07	Option Exercise	2.78	16,860	46,871	24,217	Dec 09 04:07 PM
KELER TIBOR	EXECUTIVE VP & CSO	Dec 07	Sale	36.93	16,860	622,611	7,357	Dec 09 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLDX | Celldex Therapeutics Inc.

Upgrade your FINVIZ experience